Enzalutamide/enzalutamide domestic price

Enzalutamide is available in China/Enzalutamide. The drug has been approved by the National Medical Products Administration in China for the treatment of adult patients with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer who have failed androgen deprivation therapy and have not received chemotherapy. It is sold in the form of enzalutamide soft capsules (Anchortan) and is also included in the reimbursement scope of Class B medical insurance. The common specification on the market is packaging of 40mg*112 capsules, which is sold for around RMB 6,000.

In addition, many domestic companies are also developing the generic drug market of enzalutamide, and generic drugs have been approved for marketing, providing patients with more medication options. Therefore, for patients who need enzalutamide treatment, this drug is available in China. At the same time, patients should follow medical instructions when using medications to ensure their safety and effectiveness.

Enzalutamide is a selective, silent antagonist of the androgen receptor (AR), the biological target of androgens such as testosterone and dihydrotestosterone (DHT). Unlike the first-generation NSAA bicalutamide, enzalutamide does not promote the translocation of AR to the nucleus. In addition, it blocks the binding of AR to deoxyribonucleic acid (DNA) and the binding of AR to coactivator proteins.

In addition, enzalutamide original drugs or generic drugs are sold overseas in some areas. Their drug ingredients are basically the same, but they are different in price. For example, in Turkey, the price of original drugs of the same specifications may exceed 10,000 yuan; the price of generic drugs of the same specifications produced by pharmaceutical factories in Laos and India is about more than 2,000 yuan. This price will also be affected by the exchange rate.